Impact Of Underlying Pulmonary Diseases On Treatment Outcomes In Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiotherapy

References

• Donington J, Ferguson M, Mazzone P, et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest. 2012;142(6):1620–1635. doi:10.1378/chest.12-079023208335
   PubMed Web of Science ®Google Scholar
• Zhai R, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest. 2014;145(2):346–353. doi:10.1378/chest.13-117624008835
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Kage H, Murakawa T, et al. Worse prognosis for stage IA lung cancer patients with smoking history and more severe chronic obstructive pulmonary disease. Ann Thorac Cardiovasc Surg. 2015;21(3):194–200. doi:10.5761/atcs.oa.14-0020025641032
   PubMed Web of Science ®Google Scholar
• Saito Y, Kawai Y, Takahashi N, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92(5):1812–1817. doi:10.1016/j.athoracsur.2011.06.05521944440
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16(7):807–821. doi:10.6004/jnccn.2018.006230006423
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8–11. doi:10.1513/pats.200404-032MS16113462
   PubMedGoogle Scholar
• Moro-Sibilot D, Aubert A, Diab S, et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J. 2005;26(3):480–486. doi:10.1183/09031936.05.0014600416135732
   PubMed Web of Science ®Google Scholar
• Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol. 2003;67(3):275–283. doi:10.1016/s0167-8140(03)00119-112865175
   PubMed Web of Science ®Google Scholar
• Takeda A, Kunieda E, Ohashi T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest. 2012;141(4):858–866. doi:10.1378/chest.11-119321885726
   PubMed Web of Science ®Google Scholar
• Zhou Z, Song X, Wu A, et al. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. Sci Rep. 2017;7(1):2748. doi:10.1038/s41598-017-02739-428584268
   PubMed Web of Science ®Google Scholar
• King TE Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–1961. doi:10.1016/S0140-6736(11)60052-421719092
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Okazaki T, Matsukura T, et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication? Ann Thorac Surg. 2003;76(5):1674–1678; discussion 1679. doi:10.1016/s0003-4975(03)00966-4
   Web of Science ®Google Scholar
• Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003;125(6):1321–1327. doi:10.1016/s0022-5223(03)00028-x12830051
   PubMed Web of Science ®Google Scholar
• Kushibe K, Kawaguchi T, Takahama M, Kimura M, Tojo T, Taniguchi S. Operative indications for lung cancer with idiopathic pulmonary fibrosis. Thorac Cardiovasc Surg. 2007;55(8):505–508. doi:10.1055/s-2007-96564518027337
   PubMed Web of Science ®Google Scholar
• Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147(1):157–164. doi:10.1378/chest.14-035925166895
   PubMed Web of Science ®Google Scholar
• Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012;141(1):222–231. doi:10.1378/chest.11-106222215830
   PubMed Web of Science ®Google Scholar
• Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology. 2011;16(2):326–331. doi:10.1111/j.1440-1843.2010.01907.x21114711
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique–1995 update. Am J Respir Crit Care Med. 1995;152(6 Pt 1):2185–2198. doi:10.1164/ajrccm.152.6.85207968520796
   PubMed Web of Science ®Google Scholar
• Choi JK, Paek D, Lee JO. Normal Predictive Values of Spirometry in Korean Population. Tuberc Respir Dis 2005;58(3):230–242.
   Google Scholar
• Harvey BG, Strulovici-Barel Y, Kaner RJ, et al. Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity. Eur Respir J. 2015;46(6):1589–1597. doi:10.1183/13993003.02377-201426541521
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi:10.1164/rccm.2009-040GL21471066
   PubMed Web of Science ®Google Scholar
• Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–593. doi:10.1183/09031936.05.0002100516204587
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–714. doi:10.1097/JTO.0b013e31812f3c1a17762336
   PubMed Web of Science ®Google Scholar
• Matsushita H, Tanaka S, Saiki Y, et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995;45(12):925–932. doi:10.1111/j.1440-1827.1995.tb03417.x8808297
   PubMed Web of Science ®Google Scholar
• Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg. 2008;136(5):1357–1363, 1363 e1351–1352. doi:10.1016/j.jtcvs.2008.07.016
   Web of Science ®Google Scholar
• Kwak N, Park CM, Lee J, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med. 2014;108(3):524–530. doi:10.1016/j.rmed.2013.11.01324462477
   PubMed Web of Science ®Google Scholar
• Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology. 2010;15(2):265–271. doi:10.1111/j.1440-1843.2009.01676.x20051048
   PubMed Web of Science ®Google Scholar
• Otsuka H, Sugino K, Hata Y, et al. Clinical features and outcomes of patients with lung cancer as well as combined pulmonary fibrosis and emphysema. Mol Clin Oncol. 2016;5(3):273–278. doi:10.3892/mco.2016.95427602222
   PubMedGoogle Scholar
• Fukui M, Suzuki K, Matsunaga T, Oh S, Takamochi K. Outcomes of lung cancer resection for patients with combined pulmonary fibrosis and emphysema. Surg Today. 2016;46(3):341–347. doi:10.1007/s00595-015-1234-z26276308
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa170993728885881
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa160677427718847
   PubMed Web of Science ®Google Scholar
• Shin SH, Park HY, Im Y, et al. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. Int J Cancer. 2019. doi:10.1002/ijc.32235
   Web of Science ®Google Scholar
• Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol. 2019;5:1283. doi:10.1001/jamaoncol.2019.1449
   PubMed Web of Science ®Google Scholar
• Theelen W, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1276. doi:10.1001/jamaoncol.2019.1478
   PubMed Web of Science ®Google Scholar
• Kasmann L, Niyazi M, Blanck O, et al. Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: a systematic review. Strahlenther Onkol. 2018;194(2):79–90. doi:10.1007/s00066-017-1221-y29030654
   PubMed Web of Science ®Google Scholar
• Elsayad K, Samhouri L, Scobioala S, Haverkamp U, Eich HT. Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer? J Cancer Res Clin Oncol. 2018;144(6):1165–1171. doi:10.1007/s00432-018-2640-629623466
   PubMed Web of Science ®Google Scholar